Johnson & Johnson $JNJ Shares Purchased by CORDA Investment Management LLC.

Key Points

• CORDA Investment Management LLC increased its holdings in Johnson & Johnson by 3.3% during the second quarter, owning 214,668 shares valued at approximately $32.79 million.
• Wall Street analysts have favorable forecasts for JNJ, with an average target price of $200.06 and a consensus rating of "Moderate Buy."
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, yielding about 2.7%, with the payment scheduled for December 9th.

CORDA Investment Management LLC. lifted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 214,668 shares of the company's stock after purchasing an additional 6,913 shares during the quarter. Johnson & Johnson comprises about 2.4% of CORDA Investment Management LLC.'s portfolio, making the stock its 17th biggest position. CORDA Investment Management LLC.'s holdings in Johnson & Johnson were worth $32,791,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Lorne Steinberg Wealth Management Inc. boosted its position in shares of Johnson & Johnson by 13.1% in the 2nd quarter. Lorne Steinberg Wealth Management Inc. now owns 36,006 shares of the company's stock worth $5,500,000 after purchasing an additional 4,170 shares in the last quarter. FLC Capital Advisors boosted its position in shares of Johnson & Johnson by 16.8% in the 2nd quarter. FLC Capital Advisors now owns 13,769 shares of the company's stock worth $2,103,000 after purchasing an additional 1,982 shares in the last quarter. Lyell Wealth Management LP boosted its position in shares of Johnson & Johnson by 19.6% in the 2nd quarter. Lyell Wealth Management LP now owns 7,662 shares of the company's stock worth $1,170,000 after purchasing an additional 1,257 shares in the last quarter. Accretive Wealth Partners LLC boosted its position in shares of Johnson & Johnson by 1.1% in the 2nd quarter. Accretive Wealth Partners LLC now owns 15,859 shares of the company's stock worth $2,423,000 after purchasing an additional 171 shares in the last quarter. Finally, LMG Wealth Partners LLC boosted its position in shares of Johnson & Johnson by 2.8% in the 2nd quarter. LMG Wealth Partners LLC now owns 28,137 shares of the company's stock worth $4,298,000 after purchasing an additional 763 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent analyst reports. Bank of America raised their price objective on Johnson & Johnson from $198.00 to $204.00 and gave the stock a "neutral" rating in a research report on Wednesday, October 15th. Barclays increased their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Sanford C. Bernstein increased their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the company a "market perform" rating in a report on Monday, October 6th. Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the company an "overweight" rating in a report on Friday, October 3rd. Finally, Daiwa America raised Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a report on Monday. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $200.06.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $191.93 on Wednesday. The stock has a 50-day simple moving average of $181.27 and a two-hundred day simple moving average of $165.37. The firm has a market capitalization of $462.23 billion, a P/E ratio of 18.53, a PEG ratio of 2.28 and a beta of 0.40. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.48. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. On average, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson's dividend payout ratio (DPR) is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.